| 1 |
30560227 | Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry. | 2019 Jan 1 |
1 |
| 2 |
30603867 | Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. | 2019 Jun |
1 |
| 3 |
29498469 | Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. | 2018 Jul |
2 |
| 4 |
29645341 | Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. | 2018 Aug |
1 |
| 5 |
30117055 | Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. | 2018 Oct |
1 |
| 6 |
28408838 | DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes. | 2017 |
1 |
| 7 |
26589238 | Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. | 2016 |
1 |
| 8 |
26652227 | Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. | 2016 Apr |
1 |
| 9 |
27042423 | Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. | 2016 Mar-Apr |
1 |
| 10 |
27568179 | Glucagon and heart in type 2 diabetes: new perspectives. | 2016 Aug 27 |
2 |
| 11 |
25812382 | [Significance of glucagon control in the diabetes treatment]. | 2015 Mar |
1 |
| 12 |
25999728 | Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. | 2015 |
1 |
| 13 |
24391442 | Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. | 2014 |
2 |
| 14 |
24947356 | GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. | 2014 Oct |
1 |
| 15 |
25175981 | Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. | 2014 Aug 29 |
1 |
| 16 |
25204760 | Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release. | 2014 Dec |
1 |
| 17 |
23186950 | Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. | 2013 Jan-Feb |
1 |
| 18 |
24843724 | Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients. | 2013 Nov 27 |
1 |
| 19 |
21752172 | Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. | 2012 Feb |
1 |
| 20 |
22149373 | Metformin + saxagliptin for type 2 diabetes. | 2012 Jan |
2 |
| 21 |
22986920 | Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. | 2012 Nov |
1 |
| 22 |
23214078 | [Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)]. | 2012 Nov |
1 |
| 23 |
21554520 | Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. | 2011 Sep |
1 |
| 24 |
21923696 | Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. | 2011 Oct |
1 |
| 25 |
19128990 | The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. | 2010 Mar |
2 |
| 26 |
20460554 | Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. | 2010 Jun |
1 |
| 27 |
20463416 | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. | 2010 May |
1 |
| 28 |
20824239 | Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. | 2010 Sep |
1 |
| 29 |
21189532 | [Medication of the month. Sitagliptin-metformin fixed combination (Janumet)]. | 2010 Nov |
1 |
| 30 |
18957505 | Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. | 2009 Jan |
1 |
| 31 |
20409967 | Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. | 2009 Jul-Aug |
2 |
| 32 |
18319497 | Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. | 2008 Mar 15 |
2 |
| 33 |
18806525 | Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. | 2008 Sep-Oct |
1 |
| 34 |
18820816 | Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. | 2008 Aug |
1 |
| 35 |
18929237 | Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. | 2008 Nov |
1 |
| 36 |
17190843 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. | 2007 Jan |
1 |
| 37 |
17655515 | Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. | 2007 Aug |
2 |
| 38 |
18084670 | DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. | 2007 Fall |
1 |
| 39 |
30736119 | DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. | 2007 Sep |
1 |
| 40 |
16929363 | Biologic actions and therapeutic potential of the proglucagon-derived peptides. | 2005 Nov |
1 |
| 41 |
15126524 | Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. | 2004 May |
2 |
| 42 |
11111019 | Metabolism of glucagon by dipeptidyl peptidase IV (CD26). | 2001 Jan 12 |
5 |